1. Search Result
Search Result
Results for "

dipeptidyl peptidase-4

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Peptides

4

Natural
Products

8

Recombinant Proteins

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14892A

    LC15-0444 tartrate

    Dipeptidyl Peptidase Metabolic Disease
    Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin tartrate
  • HY-P2543

    Neuropeptide Y Receptor Metabolic Disease
    Neuropeptide Y (3-36) (human, rat), a neuropeptide Y (NPY) metabolite formed from dipeptidyl peptidase-4 (DPP4), is a selective Y2 receptor agonist. Neuropeptide Y (3-36) (human, rat) is a NPY metabolite formed from dipeptidyl peptidase-4 (DPP4). Neuropeptide Y (3-36) (human, rat) decreases release of norepinephrine via the Y2 receptor .
    Neuropeptide Y (3-36) (human, rat)
  • HY-N10362

    Dipeptidyl Peptidase Metabolic Disease
    Ellipyrone B, an antihyperglycemic γ-pyrone enclosed macrocyclic polyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.48 mM) .
    Ellipyrone B
  • HY-N10360

    Dipeptidyl Peptidase Metabolic Disease
    Ellipyrone A, a γ-pyrone enclosed macrocyclic poyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.35 mM). Ellipyrone A also has anti-carbolytic property against α-glucosidase (IC50=0.74 mM) and α-amylase (IC50=0.59 mM) .
    Ellipyrone A
  • HY-N8134

    Dipeptidyl Peptidase Metabolic Disease
    2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one is a natural product found in the leaves and stem bark of M. glabra. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one displays binding affinities with dipeptidyl peptidase-4 (DPP-4) and α-Amylase. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one has potential antidiabetic activities .
    2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one
  • HY-10286A

    PHX-1149

    Dipeptidyl Peptidase Metabolic Disease
    Dutogliptin tartrate (PHX-1149) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.
    Dutogliptin tartrate
  • HY-10286

    PHX-1149 free base

    Dipeptidyl Peptidase Metabolic Disease
    Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.
    Dutogliptin
  • HY-112668
    Retagliptin phosphate
    1 Publications Verification

    SP2086 phosphate

    Dipeptidyl Peptidase Metabolic Disease
    Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research .
    Retagliptin phosphate
  • HY-112668A
    Retagliptin
    1 Publications Verification

    SP2086

    Dipeptidyl Peptidase Metabolic Disease
    Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research .
    Retagliptin
  • HY-10285
    Saxagliptin
    4 Publications Verification

    BMS-477118

    Dipeptidyl Peptidase Metabolic Disease
    Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research .
    Saxagliptin
  • HY-10285A
    Saxagliptin hydrate
    4 Publications Verification

    BMS-477118 hydrate

    Dipeptidyl Peptidase Metabolic Disease
    Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research .
    Saxagliptin hydrate
  • HY-16448
    Saxagliptin hydrochloride
    4 Publications Verification

    BMS-477118 hydrochloride

    Dipeptidyl Peptidase Metabolic Disease
    Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research .
    Saxagliptin hydrochloride
  • HY-163335

    Glutathione Peroxidase Dipeptidyl Peptidase Glucosidase Cardiovascular Disease Inflammation/Immunology
    MPO-IN-7 (compound MDC) is a myeloperoxidase inhibitor with the IC50 values of 41 μM, 25 μM and 4.5 μM towards α-Glucosidase, dipeptidyl peptidase-4 and myeloperoxidase, respectively. MPO-IN-7 shows antioxidant and anti-inflammatory activity in vitro .
    MPO-IN-7
  • HY-112668B

    SP2086 hydrochloride

    Others Others
    Retagliptin (SP2086) hydrochloride is a potent inhibitor of beta-amino acids and dipeptidyl peptidase-4 (DPP-4). Retagliptin (SP2086) hydrochloride inhibits type 2 diabetes and improves glycemic control by prolonging the action of intestinal hormones such as glucagon-like peptide-1 (GLP-1) .
    Retagliptin hydrochloride
  • HY-P1141

    GCGR Metabolic Disease
    GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .
    GLP-1(9-36)amide
  • HY-10285R

    Dipeptidyl Peptidase Metabolic Disease
    Saxagliptin (Standard) is the analytical standard of Saxagliptin. This product is intended for research and analytical applications. Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research .
    Saxagliptin (Standard)
  • HY-P1141A

    GCGR Metabolic Disease
    GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .
    GLP-1(9-36)amide TFA
  • HY-14892

    LC15-0444

    Dipeptidyl Peptidase Metabolic Disease Cancer
    Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin
  • HY-155704

    Others Others
    DPP-IV-IN-5 is isolated from the fruits of Lycium barbarum. DPP-IV-IN-5 exerts moderate agonistic activities for peroxisome proliferator-activated receptor (PPARγ) with EC50 values of 10.09 - 44.26 μM and also presents inhibitory activity on dipeptidyl peptidase-4 (DPPIV) with an IC50 value of 47.13 μM .
    Lyciumamide A
  • HY-163332

    Glucosidase Dipeptidyl Peptidase Glutathione Peroxidase Cardiovascular Disease
    MPO-IN-6 (compound ADC) is an electrophile with good antioxidant and anti-inflammatory properties. MPO-IN-6 is a myeloperoxidase (MPO), dipeptidyl peptidase-4 (DPP-4), and α-glucosidase (α-GD) inhibitor with IC50s of 10 μM, 31.02 μM, and 46.05 μM, respectively. MPO-IN-6 is a potential cardiovascular preventive agent .
    MPO-IN-6
  • HY-14877
    Anagliptin
    3 Publications Verification

    SK-0403

    Dipeptidyl Peptidase Cardiovascular Disease Metabolic Disease
    Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively .
    Anagliptin
  • HY-14877A

    SK-0403 hydrochloride

    Dipeptidyl Peptidase Cardiovascular Disease Metabolic Disease
    Anagliptin (SK-0403) hydrochloride is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively .
    Anagliptin hydrochloride
  • HY-15981

    MK-3102

    Dipeptidyl Peptidase Neurological Disease Metabolic Disease
    Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction .
    Omarigliptin
  • HY-151383

    Dipeptidyl Peptidase Metabolic Disease
    DPP-4-IN-1 (compound d1) is a potent DPP-4 (dipeptidyl peptidase 4) inhibitor, with an IC50of 49 nM. DPP-4-IN-1 is a structurally analogs of Alogliptin (HY-A0023A). DPP-4-IN-1 can be used for diabetes research .
    DPP-4-IN-1
  • HY-151384

    Dipeptidyl Peptidase Metabolic Disease
    DPP-4-IN-2 (compound b2) is a potent DPP-4 (dipeptidyl peptidase 4) inhibitor, with an IC50of 79 nM. DPP-4-IN-2 is a structurally analogs of Alogliptin (HY-A0023A). DPP-4-IN-2 can be used for diabetes research .
    DPP-4-IN-2
  • HY-15981R

    Dipeptidyl Peptidase Neurological Disease Metabolic Disease
    Omarigliptin (Standard) is the analytical standard of Omarigliptin. This product is intended for research and analytical applications. Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction .
    Omarigliptin (Standard)
  • HY-158315

    Dipeptidyl Peptidase Inflammation/Immunology
    NZ-97 is an inhibitor for dipeptidyl peptidase 4 (DPP4) with an IC50 of 18 nM. NZ-97 exhibits a low initial plasma exposure with Cmax of 0.13 µM, which is eliminated in 8 h. NZ-97 ameliorates damage in the Lipopolysaccharides (HY-D1056)-induced lung injury and Bleomycin (HY-108345)-induced lung fibrosis in mice model .
    NZ-97
  • HY-147257

    HSK7653

    Dipeptidyl Peptidase Metabolic Disease
    Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
    Cofrogliptin
  • HY-155027

    Dipeptidyl Peptidase TNF Receptor Interleukin Related Inflammation/Immunology Cancer
    DPP-4-IN-8 (compound 27) is a potent and selective DPP4 (dipeptidyl peptidase 4) inhibitor, with a Ki of 0.96 μM. DPP-4-IN-8 blocks the dipeptidase activity of DPP4 in both Caco-2 and HepG-2 cells. DPP-4-IN-8 also dose-dependently suppresses the expression levels of the chemokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) .
    DPP-4-IN-8
  • HY-N9725

    16ξ-Hydroxycleroda-3,13-dien-15,16-olide

    Dipeptidyl Peptidase Metabolic Disease
    16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy .
    16-Hydroxycleroda-3,13-dien-15,16-olide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: